Delcath Systems (DCTH) Reports Q3 Loss of $0.12/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Delcath Reports 2015 Third Quarter Financial Results
November 10, 2015 8:30 AM ESTNEW YORK, Nov. 10, 2015 /PRNewswire/ --Â Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and nine months ended September 30, 2015.Â
Financial and other highlights for the third quarter of 2015 and recent weeks included:
84% increase in total revenue compared with the third quarter of 2014 23% decrease in total operating expenses compared with the third quarter of 2014 Establishment of national reimbursement coverage for CHEMOSAT®... More